MiMedx Group, Inc. reported net sales of $88 million for the first quarter of 2025, an increase of 4% year-over-year. The company achieved GAAP net income of $7 million, or $0.05 per share, and an Adjusted EBITDA of $17 million, representing 20% of net sales.
Surgical products demonstrated strong performance with 16% growth, driven by AMNIOEFFECT and contributions from HELIOGEN. However, wound product sales experienced a 2% decline compared to the prior year period.
CEO Joseph H. Capper noted the further delay to the Local Coverage Determinations (LCDs) as a disappointing setback. To navigate this gap, MiMedx has added CELERA to its portfolio and plans to introduce additional products throughout the year, while reaffirming its 2025 net sales growth expectation of at least high single-digits and an Adjusted EBITDA margin above 20%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.